AFP obviously is a good marker for chemotherapy response and thus reduction of tumor mass, and therefore a high value at the time of pLTx and a lower decrease during therapy could be correlated to the risk of tumor recurrence and thus survival. The gene discussed is AFP; the disease is neoplasm.